Avicanna (TSE:AVCN)
TSX:AVCN
Want to see TSE:AVCN full AI Analyst Report?
AVCN Stock Chart & Stats
C$0.22
C$0.02(4.41%)
At close: 4:00 PM EST
C$0.22
C$0.02(4.41%)
Day’s Range― - ―
52-Week RangeC$0.12 - C$0.31
Previous CloseN/A
Volume8.50K
Average Volume (3M)55.79K
Market Cap
C$16.35M
Enterprise ValueC$15.98M
Total Cash (Recent Filing)C$372.10K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding125,791,870
10 Day Avg. Volume77,161
30 Day Avg. Volume55,794
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.08
Price to Sales (P/S)1.01
P/FCF Ratio-17.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginsA sustained gross margin improvement to 53% (≈+10pp) reflects better product economics and cost discipline. Higher gross profit per dollar of revenue materially improves the structural ability to reach adjusted-EBITDA breakeven and supports reinvestment for scaling without relying solely on external capital.
Debt-Free Balance SheetZero reported debt and restored positive equity materially lower financial risk and refinancing pressure. This balance-sheet repair gives management flexibility to fund R&D, clinical programs and international expansion from internal liquidity or modest raises, increasing resilience during commercialization.
R&D, IP And Clinical ProgressProprietary delivery platforms, patent activity and ongoing Phase I/II trials plus a 450‑patient RWE study create durable product differentiation and regulatory pathways. These scientific and IP assets increase long-term commercialization optionality and support higher-margin specialty products.
Bears Say
Negative Operating Cash FlowOperating and free cash flow remain negative, meaning the business continues to consume cash to operate and invest. Persistent cash burn limits the company's ability to self-fund faster commercial scaling, raises the probability of future equity raises, and constrains strategic optionality.
Still UnprofitableAlthough margins and adjusted EBITDA show improvement, full-year results remain loss-making. Continued net losses and negative operating margins mean the company has not yet converted operational gains into sustained profitability, limiting internal reinvestment and increasing execution risk if margins slip.
Flat Revenue And Market ConcentrationFlat annual revenue and a domestic sales concentration indicate limited top-line momentum. With international revenue still small, scaling benefits from new IP and delivery platforms depend on successful market entries and regulatory navigation, prolonging the timeline to meaningful, diversified growth.
Avicanna News
AVCN FAQ
What was Avicanna’s price range in the past 12 months?
Avicanna lowest stock price was C$0.12 and its highest was C$0.31 in the past 12 months.
What is Avicanna’s market cap?
Avicanna’s market cap is C$16.35M.
When is Avicanna’s upcoming earnings report date?
Avicanna’s upcoming earnings report date is Aug 17, 2026 which is in 88 days.
How were Avicanna’s earnings last quarter?
Currently, no data Available
Is Avicanna overvalued?
According to Wall Street analysts Avicanna’s price is currently Overvalued.
Does Avicanna pay dividends?
Avicanna does not currently pay dividends.
What is Avicanna’s EPS estimate?
Avicanna’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avicanna have?
Avicanna has 125,791,870 shares outstanding.
What happened to Avicanna’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avicanna?
Currently, no hedge funds are holding shares in TSE:AVCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avicanna
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Technical Analysis
Charlotte's Web Holdings
―
MediPharm Labs
―
PharmaCielo
―
Cardiol Therapeutics
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---